Ainos (NASDAQ:AIMD) Releases Quarterly Earnings Results

Ainos (NASDAQ:AIMD) posted its earnings results on Wednesday. The company reported ($0.41) EPS for the quarter, Zacks reports. Ainos had a negative return on equity of 140.10% and a negative net margin of 11,912.10%.

Ainos Trading Up 1.8%

AIMD stock opened at $1.71 on Thursday. The business has a fifty day moving average price of $1.59 and a 200 day moving average price of $1.94. Ainos has a fifty-two week low of $1.26 and a fifty-two week high of $4.50. The stock has a market capitalization of $12.43 million, a price-to-earnings ratio of -0.48 and a beta of 2.29. The company has a debt-to-equity ratio of 1.45, a current ratio of 1.06 and a quick ratio of 0.78.

Institutional Trading of Ainos

Large investors have recently made changes to their positions in the business. DRW Securities LLC grew its holdings in shares of Ainos by 272.6% during the fourth quarter. DRW Securities LLC now owns 66,211 shares of the company’s stock worth $109,000 after purchasing an additional 48,439 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Ainos by 13.1% during the fourth quarter. Renaissance Technologies LLC now owns 66,300 shares of the company’s stock worth $109,000 after purchasing an additional 7,700 shares during the last quarter. Two Sigma Investments LP bought a new stake in shares of Ainos during the third quarter worth $80,000. Finally, Mariner LLC bought a new position in Ainos in the 4th quarter valued at $37,000.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Ainos in a research report on Friday, May 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Ainos presently has an average rating of “Sell”.

About Ainos

Ainos, Inc (NASDAQ: AIMD) is a clinical‐stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI‐401, is an inhaled formulation of ibuprofen in a dry powder format.